Table 1.
Baseline Patient Characteristics (N = 90)
| Variable | N (%) |
|---|---|
| Age (years) | |
| Median (IQR) | 63 (55, 68) |
| Male Sex | 59 (66) |
| Tumor Histology | |
| Clear Cell | 74 (82) |
| Papillary | 7 (8) |
| Chromophobe | 2 (2) |
| Other | 7 (8) |
| Site of Metastases | |
| Lung | 28 (31) |
| Liver | 7 (8) |
| Bone | 10 (11) |
| Brain | 1 (1) |
| Other | 14 (16) |
| Unknown | 30 (33) |
| Prior Nephrectomy | 70 (78) |
| Prior Systemic RCC Therapy | |
| None | 78 (87) |
| IL-2 | 7 (8) |
| Other Targeted Agent | 5 (6) |
| Sunitinib Starting Dose | |
| 50 mg | 55 (61) |
| 37.5 mg | 4 (4) |
| 25 mg | 6 (7) |
| Other (Escalating Dose) | 25 (28) |
| Baseline LVEF (%) | |
| Median (IQR) | 49.8 (44.6, 54.1) |
| Baseline Cardiac Troponin I (pg/ml) | |
| Median (IQR) | 1.7 (1.0 – 3.6) |
| Baseline BNP (pg/ml) | |
| Median (IQR) | 32.8 (16.7 – 65.4) |
| Baseline SBP (mmHg) | |
| Median (IQR) | 135 (123, 147) |
| Baseline Pulse Pressure (mmHg) | |
| Median (IQR) | 58 (47, 70) |
| Baseline Dyspnea Severitya | 0 (0, 2) |
| Baseline MDASI-HF Scorea | 0.6 (0.2, 1.5) |
|
Cardiovascular Co-morbidities/Risk Factors |
|
| Hypertension | 49 (54) |
| Coronary Disease | 8 (9) |
| Heart Failure | 4 (4) |
| BMI (median, IQR) | 27.0 (23.7, 32.9) |
| Hyperlipidemia | 47 (52) |
| Diabetes Mellitus | 22 (24) |
| Tobacco Use | 51 (57) |
| Cardiac Medication Use | |
| Aspirin | 23 (26) |
| ACEi or ARB | 24 (27) |
| Beta Blocker | 20 (22) |
| Calcium Channel Blocker | 19 (21) |
| Statin | 28 (31) |
Abbreviations: RCC, renal cell carcinoma; IQR, interquartile range; IL-2, interleukin-2; LVEF, left ventricular ejection fraction; BNP, B-type natriuretic peptide; SBP, systolic blood pressure; BMI, body mass index; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; Statin, HMG CoA reductase inhibitor
a
Symptoms assessed by the MD Anderson Symptom Inventory – Heart Failure and scored on a scale of 0–10. Heart Failure Symptom Score is derived from the average response for 8 heart failure symptoms, including severity of ankle edema, abdominal bloating, sudden weight gain, lack of energy, orthopnea, paroxysmal nocturnal dyspnea, nocturnal cough, and palpitations.